Cytosporone B
Based on 18 publication(s) in Google Scholar
Cytosporone B (Csn-B; Dothiorelone G) is a naturally occurring nuclear orphan receptor Nur77/NR4A1 agonist with an EC50 of 0.278 nM.
For research use only. We do not sell to patients.
- Purity: 98.80%
- CAS No.: 321661-62-5
- Formula: C18H26O5
- Molecular Weight:322.40
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
Publications Citing Use of MedChemExpress (MCE) Cytosporone B
More- Chem Eng J. 2025 Aug 24.
- Cell Death Dis. 2025 Oct 6;16(1):700. [Abstract]
- Int J Biol Macromol. 2026 Jun 11:373:152939. [Abstract]
- Clin Transl Med. 2021 Dec;11(12):e639. [Abstract]
- Cell Rep. 2020 Oct 20;33(3):108284. [Abstract]
- Pharm Biol. 2022 Dec;60(1):394-403. [Abstract]
- Int Immunopharmacol. 2025 Mar 6:149:114242. [Abstract]
- J Thromb Haemost. 2025 Oct 31:S1538-7836(25)00673-7. [Abstract]
- Eur J Immunol. 2026 May;56(5):e70202. [Abstract]
- Clin Transl Immunology. 2024 Apr 15;13(4):e1503. [Abstract]
- Biol Reprod. 2024 Sep 14;111(3):640-654. [Abstract]
- J Cardiovasc Transl Res. 2023 Oct;16(5):1050-1063. [Abstract]
- Chinese J Anal Chem. 17 September 202.
- Cell Press Blue. 2026 Apr 22.
- Mi-JHM. 2025 May 8.
- SSRN. 2025 Feb 6.
- medRxiv. 2024 Mar 15.
- bioRxiv. 2024 Feb 8.
-
Cell Proliferation/Viability Assay
-
WB
-
Bio/Physico-chemical Assay
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
All Nuclear Hormone Receptor 4A/NR4A Isoforms
More
Biological Activity
|
Nur77/NR4A1 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BGC-823 | EC50 |
1.15 x 10-10 M
Compound: 1, Csn-B
|
Agonist activity at nuclear orphan receptor Nur77 expressed in human BGC823 cells co-transfected with fused GAL4-LBD assessed as transactivation after 12 hrs by luciferase reporter gene assay
Agonist activity at nuclear orphan receptor Nur77 expressed in human BGC823 cells co-transfected with fused GAL4-LBD assessed as transactivation after 12 hrs by luciferase reporter gene assay
|
[PMID: 18690216] |
| BGC-823 | EC50 |
2.78 x 10-10 M
Compound: 1, Csn-B
|
Agonist activity at nuclear orphan receptor Nur77 expressed in human BGC823 cells co-transfected with fused GAL4-Nur77 assessed as transactivation after 12 hrs by luciferase reporter gene assay
Agonist activity at nuclear orphan receptor Nur77 expressed in human BGC823 cells co-transfected with fused GAL4-Nur77 assessed as transactivation after 12 hrs by luciferase reporter gene assay
|
[PMID: 18690216] |
| LNCaP | IC50 |
13.4 μM
Compound: 1, Csn-B
|
Cytotoxicity against human LNCAP cells after 72 hrs by MTT assay
Cytotoxicity against human LNCAP cells after 72 hrs by MTT assay
|
[PMID: 24795803] |
| NCI-H460 | IC50 |
15.3 μM
Compound: 1, Csn-B
|
Cytotoxicity against human H460 cells after 72 hrs by MTT assay
Cytotoxicity against human H460 cells after 72 hrs by MTT assay
|
[PMID: 24795803] |
Cytosporone B targets the ligand binding domain of Nur77, which selectively stimulates the transactivational activity of Nur77. Cytosporone B induces luciferase activity in cells that are cotransfected with GAL4- Nur77 or GAL4-LBD. The EC50 of cytosporone B for Nur77 is 0.278 nM. Cytosporone B displays robust pro-apoptotic activity in gastric cancer cells BGC-823. 63.5% of the cells are apoptotic when treated with cytosporone B for 48 h. Cytosporone B shows selective effect on cancerous cells. Cytosporone B inhibits proliferation of human gastric cancer BGC-823 cells and human colon cancer SW620 cells by 470%, but it has a modest effect on human lung cancer H1299 cells and human hepatoma HepG2 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 321661-62-5
-
Appearance Solid
-
Molecular Weight 322.40
-
Formula C18H26O5
-
Color Off-white to light yellow
-
SMILES
O=C(OCC)CC1=CC(O)=CC(O)=C1C(CCCCCCC)=O
-
Synonyms
Csn-B; Dothiorelone G
-
Structure Classification
-
Initial Source
fungus?Eupenicillium?sp. HJ002
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (18)
-
Journal Impact Factor
-
Most Recent
-
Cytosporone B purchased from MedChemExpress. Usage Cited in: Chem Eng J. 2025 Aug 24.
The viabilities of RAW264.7 cells and RSC96 cells after 24 h treatment with varying concentrations of Cytosporone B (CSNB, 4-8 μM) and SAL, respectively.
-
Cell Death Dis
PARL stabilizes mitochondrial BCL-2 via Nur77-mediated scaffolding as a therapeutic strategy for Parkinson's disease. [Abstract]2025 Oct 6;16(1):700. PMID: 41052999 -
Int J Biol Macromol
High throughput screening of nuclear receptors identifies NR4A1 as a novel tumor suppressor in gallbladder cancer. [Abstract]2026 Jun 11:373:152939. PMID: 42276489 -
Clin Transl Med
NR4A1 suppresses pyroptosis by transcriptionally inhibiting NLRP3 and IL-1β and co-localizing with NLRP3 in trans-Golgi to alleviate pathogenic bacteria-induced colitis. [Abstract]2021 Dec;11(12):e639. PMID: 34923769 -
Cell Rep
2020 Oct 20;33(3):108284. PMID: 33086070
Cytosporone B purchased from MedChemExpress. Usage Cited in: Cell Rep. 2020 Oct 20;33(3):108284. [Abstract]
Tumor weight, and tumor images of nude mice with subcutaneous injection of HeLa cells and then intraperitoneal injection DMSO and 10 mg/kg Cytosporone B (CsnB). The results showed that Cytosporone B (CsnB) inhibited tumor growth in wild-type (WT) mice, but this effect was not observed in NR4A1-deficient mice.
-
Pharm Biol
Pterostilbene pre-treatment reduces LPS-induced acute lung injury through activating NR4A1. [Abstract]2022 Dec;60(1):394-403. PMID: 35271397 -
Int Immunopharmacol
Clemastine fumarate alleviates endoplasmic reticulum stress through the Nur77/GFPT2/CHOP pathway after ischemia/reperfusion in rat hearts. [Abstract]2025 Mar 6:149:114242. PMID: 39929094 -
J Thromb Haemost
Cytosporone B ameliorates hypercoagulability in sepsis by agonizing the Nur77-thrombomodulin pathway. [Abstract]2025 Oct 31:S1538-7836(25)00673-7. PMID: 41177456
Cytosporone B purchased from MedChemExpress. Usage Cited in: J Thromb Haemost. 2025 Oct 31:S1538-7836(25)00673-7. [Abstract]
Cytosporone B (Csn-B; 5-10 μM; 1-48 h) could upregulate Nur77 expression in HUVECs in a dose- and time-dependent manner.
Cytosporone B purchased from MedChemExpress. Usage Cited in: J Thromb Haemost. 2025 Oct 31:S1538-7836(25)00673-7. [Abstract]
After transfection with siCTL or siNur77 for 48 hours, HUVECs were treated with vehicle or Cytosporone B (Csn-B) (10 μM) for 24 hours. Cells were then treated with TNF-α (100 ng/mL) for 2 hours. The results showed that Cytosporone B (Csn-B) significantly prolonged the clotting time of HUVECs stimulated by TNF-α, but this effect was abolished when Nur77 was knocked down.
Cytosporone B purchased from MedChemExpress. Usage Cited in: J Thromb Haemost. 2025 Oct 31:S1538-7836(25)00673-7. [Abstract]
Cytosporone B (Csn‑B, 13 mg/kg; i.p.; once daily for 3 days) improved the 72‑hour survival rate of mice following cecal ligation and puncture (CLP) surgery. At 5 hours after CLP, Csn‑B attenuated the shortening of tail bleeding time and prothrombin time (PT), as well as the decrease in platelet count in mice.
-
Eur J Immunol
2026 May;56(5):e70202. PMID: 42117214 -
Clin Transl Immunology
SARS-CoV-2-infected human airway epithelial cell cultures uniquely lack interferon and immediate early gene responses caused by other coronaviruses. [Abstract]2024 Apr 15;13(4):e1503. PMID: 38623540 -
Biol Reprod
NR4A1-mediated regulation of lipid droplets in progesterone synthesis in goat luteal cells†. [Abstract]2024 Sep 14;111(3):640-654. PMID: 38936833 -
J Cardiovasc Transl Res
NR4A1 Aggravates Myocardial Ischaemia-Reperfusion Injury by Inhibiting OPA1-Mediated Mitochondrial Fusion. [Abstract]2023 Oct;16(5):1050-1063. PMID: 37249897 -
-
-
-
-
-
Solvent & Solubility
DMSO : 100 mg/mL (310.17 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : ≥ 50 mg/mL (155.09 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.75 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.75 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Human gastric cancer BGC-823 cells and human colon cancer SW620 cells are treated with cytosporone B for 72 h at 0-15 μg/mL. Cell viability is measured using the MTT assay[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice: The inoculated mice are randomly separated into two groups. One group is given an injection to the abdominal cavity at a dosage of 13 mg/kg of cytosporone B twice a week. The other group is administered with DMSO without cytosporone B. Food consumption and body weight of nude mice are monitored weekly. Four weeks later, the nude mice are killed and the tumors formed are removed, fixed and embedded[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 3.1017 mL | 15.5087 mL | 31.0174 mL | 77.5434 mL |
| 5 mM | 0.6203 mL | 3.1017 mL | 6.2035 mL | 15.5087 mL | |
| 10 mM | 0.3102 mL | 1.5509 mL | 3.1017 mL | 7.7543 mL | |
| 15 mM | 0.2068 mL | 1.0339 mL | 2.0678 mL | 5.1696 mL | |
| 20 mM | 0.1551 mL | 0.7754 mL | 1.5509 mL | 3.8772 mL | |
| 25 mM | 0.1241 mL | 0.6203 mL | 1.2407 mL | 3.1017 mL | |
| 30 mM | 0.1034 mL | 0.5170 mL | 1.0339 mL | 2.5848 mL | |
| 40 mM | 0.0775 mL | 0.3877 mL | 0.7754 mL | 1.9386 mL | |
| 50 mM | 0.0620 mL | 0.3102 mL | 0.6203 mL | 1.5509 mL | |
| 60 mM | 0.0517 mL | 0.2585 mL | 0.5170 mL | 1.2924 mL | |
| 80 mM | 0.0388 mL | 0.1939 mL | 0.3877 mL | 0.9693 mL | |
| 100 mM | 0.0310 mL | 0.1551 mL | 0.3102 mL | 0.7754 mL |